A

ll the recent rancor over drug pricing has led biotech to change its ways. Not by making new drugs cheaper, of course, but by holding off on naming a price — and thus inviting controversy — until the last possible minute.

Nowadays, as soon as a drug wins Food and Drug Administration approval, so begins a debate about whether it’s worth the thousands of dollars a year new therapies generally cost. And so companies, perhaps mindful of how a few scolding tweets can snowball into a market-moving event, are starting to keep that information under wraps for as long as possible.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X